AKTHELIA

Akthelia is an preclinical stage pharmaceutical company founded by four eminent professors, two from the Karolinska Institute in Sweden and two from the University of Iceland. The company is focused on the discovery and development of therapeutics which enhance and deploy the body's own innate microbial defence mechanisms to combat debilitating diseases. This novel mechanism of action elucidated by Akthelia, underpins the development of the Company's pharmaceutical actives... Our therapeutic strategy, which is based on a depth of field-leading cell biology expertise from our science founders, is to eliminate bacterial translocation by enhancing the innate immunologic barrier resistance of the GI tract. We do this through upregulating endogenous proteins that are naturally expressed within epithelia and normally act to contain the microbiota within the gut lumen in a healthy individual. This holds the promise of a new standard of care treatment with potential to replace prophylactic..

Primary location: Reykjavik Iceland